CLINICAL_TRIALS
trial_result
· 2013-09-16
Clinical Trial Update: BIIB023 (Anti-TWEAK) in Subjects With Rheumatoid Arthritis [Phase 1]
Summary
A Phase 1 study of BIIB023, an anti-TWEAK antibody, in rheumatoid arthritis has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Biogen | Conditions: Rheumatoid Arthritis | Phase 1 | Status: COMPLETED